Evidence map›Paper›PMID 24441289›Full record

Trial reportLeukemia2014

Low-dose lenalidomide plus cytarabine induce complete remission that can be predicted by genetic profiling in elderly acute myeloid leukemia patients.

G Visani, F Ferrara, F Di Raimondo, F Loscocco, G Sparaventi, S Paolini, F Fuligni, A Gazzola, M Rossi, M A Laginestra and 7 more

Abstract readClinical Trial, Phase IILetter
PubMed Publisher
In one paragraph

Trial report in Leukemia, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

G VisaniHematology and Hematopoietic Stem Cell Transplant Center, AORMN, Pesaro, Italy.
F FerraraHematology, Cardarelli Hospital, Napoli, Italy.
F Di RaimondoHematology, Catania University, Catania, Italy.
F LoscoccoHematology and Hematopoietic Stem Cell Transplant Center, AORMN, Pesaro, Italy.
G SparaventiHematology and Hematopoietic Stem Cell Transplant Center, AORMN, Pesaro, Italy.
S PaoliniHematopathology Section, Department of Experimental, Diagnostic, and Specialty Medicine, S. Orsola-Malpighi Hospital, Bologna University School of Medicine, Bologna, Italy.
F FuligniHematopathology Section, Department of Experimental, Diagnostic, and Specialty Medicine, S. Orsola-Malpighi Hospital, Bologna University School of Medicine, Bologna, Italy.
A GazzolaHematopathology Section, Department of Experimental, Diagnostic, and Specialty Medicine, S. Orsola-Malpighi Hospital, Bologna University School of Medicine, Bologna, Italy.
M RossiHematopathology Section, Department of Experimental, Diagnostic, and Specialty Medicine, S. Orsola-Malpighi Hospital, Bologna University School of Medicine, Bologna, Italy.
M A LaginestraHematopathology Section, Department of Experimental, Diagnostic, and Specialty Medicine, S. Orsola-Malpighi Hospital, Bologna University School of Medicine, Bologna, Italy.
M R CaraciHematology, Catania University, Catania, Italy.
C RiccardiHematology, Cardarelli Hospital, Napoli, Italy.
M RocchiInstitute of Biomathematics, Urbino University, Urbino, Italy.
A VisaniHematopathology Section, Department of Experimental, Diagnostic, and Specialty Medicine, S. Orsola-Malpighi Hospital, Bologna University School of Medicine, Bologna, Italy.
S A PileriHematopathology Section, Department of Experimental, Diagnostic, and Specialty Medicine, S. Orsola-Malpighi Hospital, Bologna University School of Medicine, Bologna, Italy.
P P PiccalugaHematopathology Section, Department of Experimental, Diagnostic, and Specialty Medicine, S. Orsola-Malpighi Hospital, Bologna University School of Medicine, Bologna, Italy.
A IsidoriHematology and Hematopoietic Stem Cell Transplant Center, AORMN, Pesaro, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

AgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsCytarabineGene Expression ProfilingGene Expression Regulation, NeoplasticHumansLenalidomideLeukemia, Myeloid, AcuteProspective StudiesRemission InductionThalidomideCytarabineLenalidomideThalidomide

Identifiers

PMID24441289

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.